Approved targeted therapies that have been tested in the post-allo-HCT relapse setting include midostaurin and gilteritinib for FLT3+ AML, (73, 74) enasidenib for IDH2+ AML (75), and ivosidenib for IDH1+ AML (76). Here, IDH2 is linked to acute myeloid leukemia.